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Antimicrobial-resistant microbes are an increasing threat to human health. In cystic
fibrosis (CF), airway infections with Pseudomonas aeruginosa remain a key driver
of lung damage. With few new antibiotics on the development horizon, alternative
therapeutic approaches are needed against antimicrobial-resistant pathogens. Phage
therapy, or the use of viruses that infect bacteria, is one proposed novel therapy to treat
bacterial infections. However, the airways are complex microenvironments with unique
characteristics that may affect the success of novel therapies. Here, three phages
of P. aeruginosa (E79, F116, and one novel clinically derived isolate, designated P5)
were screened for activity against 21 P. aeruginosa strains isolated from children with
CF. Of these, phage E79 showed broad antibacterial activity (91% of tested strains
sensitive) and was selected for further assessment. E79 genomic DNA was extracted,
sequenced, and confirmed to contain no bacterial pathogenicity genes. High titre
phage preparations were then purified using ion-exchange column chromatography and
depleted of bacterial endotoxin. Primary airway epithelial cells derived from children with
CF (n = 8, age range 0.2–5.5 years, 5 males) or healthy non-CF controls (n = 8, age
range 2.5–4.0 years, 4 males) were then exposed to purified phage for 48 h. Levels
of inflammatory IL-1β, IL-6, and IL-8 cytokine production were measured in culture
supernatant by immunoassays and the extent of cellular apoptosis was measured
using a ssDNA kit. Cytokine and apoptosis levels were compared between E79-
stimulated and unstimulated controls, and, encouragingly, purified preparations of E79
did not stimulate any significant inflammatory cytokine responses or induce apoptosis
in primary epithelial cells derived from children with or without CF. Collectively, this
study demonstrates the feasibility of utilizing pre-clinical in vitro culture models to screen
therapeutic candidates, and the potential of E79 as a therapeutic phage candidate in CF.
Keywords: cystic fibrosis, phage therapy, preclinical models, airway epithelial cells, Pseudomonas aeruginosa,
infection
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INTRODUCTION
Cystic fibrosis (CF) is the most common autosomal recessive
lethal genetic disease of Caucasian populations (Tian et al., 2016).
In the lung, loss of CFTR function leads to production of viscous
mucus, which is difficult to clear by standard mucociliary action
(Koehler et al., 2004). This in turn contributes to the development
of chronic infections with opportunistic bacterial pathogens such
as Pseudomonas aeruginosa (Friman et al., 2013). The severity
of lung bronchiectasis, excessive lung inflammation in children,
and rate of decline in lung function in infants with CF is directly
correlated with airway infections with P. aeruginosa (Koehler
et al., 2004; Farrell et al., 2009; Pillarisetti et al., 2011).
Current therapies for CF lung infections include intravenous
or inhaled antibiotics (National Guideline Alliance, 2017).
However, antibiotic-resistant bacterial strains have emerged as
major causes of mortality in hospitals worldwide, and in Western
Australia, approximately 30% of P. aeruginosa isolates from
CF patients are carbapenem-resistant (Tai et al., 2015). The
World Health Organization has recognized antibiotic resistance
as a significant threat to human health requiring urgent action
(World Health Organization, 2014). Bacteriophages (phages)
are viruses that infect bacteria, and present a novel treatment
option in CF, however, little has been investigated regarding
their potential in this setting. Concomitant with this need for
new antibacterial treatments is the need for relevant in vitro
models to screen potentially therapeutic phages and facilitate
understanding of how these preparations act in the context
of the human airway (Trend et al., 2017). Phage therapy
holds enormous potential benefit for people with CF, and may
complement existing antimicrobial strategies, since phages can
replicate at the site of infection inside the target bacterial cells and
subvert existing antimicrobial resistance in bacterial pathogens
(Alemayehu et al., 2012; Sahota et al., 2015).
While the investigation and development of phage-derived
products as therapeutic agents requires employment of in vitro
antimicrobial assays, the effectiveness of any antimicrobial
therapy in vivo may not always correspond to expected outcomes,
due to a range of human factors not considered in the models
(Henry et al., 2013). For example, host immune mediators
directly interact with phage particles to inactivate them in vivo
(Majewska et al., 2015). Furthermore, the patient’s innate
immune system may induce an inflammatory response upon
exposure to the phage, particularly if the phage preparations
derived from culture in bacterial hosts are inadequately purified.
Relevant in vitro models are thus essential in order to elucidate
and understand the responses of the airway to this new potential
therapy.
To develop phages for clinical trials, researchers should
characterize and screen candidates for antimicrobial activity and
carriage of bacterial pathogenicity genes. Given the inflammatory
nature of many bacterial-derived products, stringent purification
steps must be applied to phage preparations after propagation
in bacterial hosts (Merabishvili et al., 2009), the success of
which can then be confirmed on human cells using relevant
exposure models. Previous investigations of this type have
utilized immortal cell lines or animal models. Although the ability
to screen the suitability of phage preparations using human CF
airways cells would lead to more relevant findings, investigations
involving primary airway epithelial cells have traditionally been
limited due to their restricted expansion potential (Lane et al.,
2005). However, our laboratory has recently described the
development of an in vitro culture expansion methodology of
primary airway epithelial cells in a realistic model of the airway
(Martinovich et al., 2017). Using primary airway cells derived
utilizing this technique, we performed screening analyses of a
number of phages. Due to its broad range of activity against
CF clinical isolates, phage E79 was purified using ion-exchange
chromatography and endotoxin depleted to clinically acceptable
levels. We showed that purified E79 does not induce apoptosis
or inflammatory cytokine production in primary airway cells
derived from children with CF or healthy non-CF individuals
exposed to the phage preparations for 48 h. Moreover, the phage
was virulent, stable, and genome sequencing did not reveal
any known bacterial virulence genes. Collectively, these findings
suggest that E79 may be a good candidate for phage therapy.
MATERIALS AND METHODS
Bacteriophage and Bacterial Sources
and Culture
E79 and F116 bacteriophages (Slayter et al., 1964) were
obtained from the University of Western Australia Department
of Microbiology Culture Collection (MCC), and utilized as
examples of virulent and temperate phages to compare to
novel phage isolates. Novel P. aeruginosa phage P5 was
isolated from pediatric CF patient sputum. A panel of 21
isolates of P. aeruginosa (designated PMH-) were derived from
sputum of patients with CF-related infections, supplied by
PathWest Laboratory Medicine, Perth, Western Australia. An
independent collection of 14 isolates of P. aeruginosa isolated
from sputa of children with CF were derived from the AREST
CF culture collection (designated ARESTCF-). Reference strain
PAO1 (Dunn and Holloway, 1971) was obtained from MCC.
P. aeruginosa strains were routinely propagated in heart infusion
agar (HIA) or broth (HIB) aerobically at 37◦C.
Antimicrobial Susceptibility of Clinical
P. aeruginosa Isolates
Sensitivity of 14 clinical isolates (AREST CF collection)
of P. aeruginosa to gentamicin, ceftazidime, meropenem,
amikacin, piperacillin, cefepime, tobramycin, ciprofloxacin,
norfloxacin, timentin, piperacillin/tazobactam, and aztreonam
was determined by the Royal Children’s Hospital Melbourne
pathology laboratory using disk diffusion assays. Susceptibility
was determined according to Clinical and Laboratory Standards
Institute (CLSI) breakpoints (CLSI, 2016).
Isolation of Clinically Derived Phages
Sputa from 20 CF patients were screened for the presence
of phages that were able to infect any member of the panel
of 21 clinical P. aeruginosa isolates (PMH collection). Sputa
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were mixed, and large materials sedimented by centrifugation
at 1,750 × g for 20 min at room temperature (RT). Following
filter-sterilization of the supernatant using a 0.22 µm pore sterile
membrane, an aliquot (10 µL) was pipetted onto a lawn of
each bacterial strain as described for phage propagation. Plaques
appearing on bacterial lawns, either derived from sputa or
from lysogenic phage spontaneously induced from the bacterial
genome, were transferred to 150 µL of phage buffer (Tris–
HCl 10 mM, MgCl2 10 mM [pH 8]) (Matsumoto et al., 1986).
The suspension was purified as described for phage propagation
and tested for phage titre. Phages were plaque-purified twice,
prepared at high titre and stored at 4◦C.
Phage Imaging and Classification
Electron microscopy was performed on phage suspensions
that were purified using a modified methodology (Bruttin and
Brussow, 2005). Briefly, following centrifugation at 4,000 × g
for 15 min at RT the resulting supernatant was separated by
centrifugation at 35,000 × g for 25 min at RT. The phage-
containing pellet was resuspended and applied to carbon-
coated formvar grids for 5 min, which were charged prior to
phage co-incubation using 1% (w/v) Alcian blue. Grids were
negatively stained for 10 min using a 2% sodium silicotungstate
solution, dried at RT, then analyzed using Transmission Electron
Microscopy (TEM) using a Philips 401 TE microscope. Phage
head, tail, and sheath sizes were measured, and data presented as
a mean and standard deviation of three particle measurements.
For classification, phage genetic material was treated with
the class II restriction endonucleases, either BamHI or HindIII,
for 2 h at 37◦C. A 2 µL sample was then combined with
3 µL of tracking dye containing bromophenol blue (2.5 mg/mL)
and sucrose (400 mg/mL) and electrophoresed on a 0.8% (w/v)
agarose gel containing ethidium bromide (10 µg/mL) in Tris-
Acetate Buffer with Ethylenediaminetetraacetic acid (0.5 M) for
60 min at 90 V. The gel was then photographed using UV
illumination to detect if multiple bands were present, indicating
digested DNA. The genome size was estimated by comparison to
a HindIII ladder, while the genome sequencing results provided a
more precise genome size.
Phage Propagation and Host Range
Phages were propagated to high titre according to a modified
version of the double agar layer method (Adams, 1959). Molten
overlay agar containing 1% Bacto agar and HIB, supplemented
with calcium and magnesium (0.01 M) was mixed with an
aliquot of overnight broth culture of host bacteria and phage at
approximately 105 PFU/mL. The mixture was overlaid onto a
HIA plate, allowed to set at RT and then incubated overnight
at 37◦C in 5% CO2. The following day, the overlay agar with
semi-confluent phage plaques was scraped off the HIA plate and
mixed with 3.5 mL of isotonic saline. All phage preparations were
preliminarily purified by mixing followed by centrifugation at
1,750× g at RT. The supernatant was filtered through a 0.22 µm
pore-size membrane. Phage titre was then determined using the
drop-on plate method. Briefly, 10µL of 10-fold dilutions of phage
preparations were dropped in triplicate onto a HIA plate overlaid
with overlay agar containing an overnight culture of PAO1,
and the plaques in the bacterial lawn counted after incubation
overnight at 37◦C in 5% CO2.
Host range experiments were carried out on 21 clinical
P. aeruginosa strains. Sensitivity to a phage was determined by
a zone of clearing or plaques on a bacterial lawn where 10 µL
of high titre phage preparation (108–1012 PFU/mL) was spotted
onto the lawn in triplicate, followed by incubation at 37◦C
overnight.
Growth Inhibition by E79
The inhibitory capacity of E79 for clinical P. aeruginosa isolates
(AREST CF collection) was determined using the following
method. Briefly, bacteria were grown to approximately 0.5
MacPharland standard (∼1 × 108 CFU/mL,) determined by
spectroscopy and 100 µL of bacterial suspension was then added
to wells of a 96-well flat-bottom polypropylene plate. E79 was
diluted to 109 PFU/mL in sterile isotonic saline, then serially
diluted in 10-fold dilutions down to 104 PFU/mL. Dilutions of
phage or a control of saline only were added in equal volumes
at a multiplicity of infection (MOI) of 10:1 and 1:1, and plates
incubated at 37◦C in 5% CO2 overnight. Optical density of wells
was then measured at 595 nm, and the percentage of growth in
treated wells quantified by dividing this value by the absorbance
in the control well. A bacterial strain was considered sensitive to
phage at that MOI if the optical density in the test well was≥10%
lower than that of the untreated well.
Phage DNA Extraction and Genome
Sequencing
High titre E79 was pre-treated with DNase I to reduce
contaminating bacterial DNA. A 200 µL aliquot containing
∼1011 PFU of phage was incubated for 30 min at 37◦C with
1 U of DNase I from the Invitrogen PureLink RNA Mini
Kit. DNA was subsequently extracted using a QIAamp DNA
mini spin column kit (QIAGEN) per manufacturer’s instructions
and sequenced (LotteryWest Sequencing Facility, University of
Western Australia, Perth, WA, Australia). The concentration of
DNA was determined using a Qubit fluorometer according to
manufacturer’s instructions. The sample (10 ng) was sheared
using a S2 ultrasonicator (Covaris) and sequencing libraries
prepared using a NEBnext Ultra library kit (New England
Biosciences). Sequencing was performed on a 318 chip using an
Ion Torrent PGM semiconductor sequencer for 820 flows. Data
were collected using Torrent Suite 5.0. Reads were imported into
CLC Genomics Workbench V 10.1.2, and de novo assembled,
before the phage genome was annotated using RASTtk (Brettin
et al., 2015). The annotated phage genome was then imported
into Geneious V10.2.4 for visualization and manual curation.
Purification of High Titre Phage
Preparation for Cellular Assays
Filter-sterilized high titre phage preparations were purified
using a CIMmultus quaternary amine (QA) advanced composite
monolithic column (BIA separations) in combination with a Bio-
Rad Econopump. Phage was diluted 1:10 in 20 mM Tris–HCl (pH
7.5) loading buffer, and 10 mL was passed through the column.
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TABLE 1 | Clinical details of CF-related characteristics in cell donors with CF at time of cell collection.
Sample CFTR genotype CFTR mutation
class
Neutrophil
elastase (nM)
Bronchiectasis
(0–12 score)
Respiratory pathogens
CF1 p.Gly85Glu/Unknown –/– 100 0 Mixed oral flora
CF2 p.Phe508del/p.Phe508del II/II 1260 n/a None
CF3 p.Phe508del/p.Phe508del II/II 270 n/a Moraxella catarrhalis, Haemophilus influenzae,
MRSA, Mixed oral flora
CF4 p.Phe508del/p.Asn1303Lys II/II 270 n/a Aspergillus fumigatus, Stenotrophomonas
maltophilia
CF5 p.Phe508del/p.Thr966ArgfsX2 #N/A 170 n/a None
CF6 p.Phe508del/Ala455Glu #N/A 70 n/a H. influenzae
CF7 p.Phe508del/p.Phe508del II/II 140 n/a Streptococcus pneumoniae
CF8 p.Phe508del/p.Phe508del II/II 60 n/a None
CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; MRSA, methicillin-resistant Staphylococcus aureus.
The column was washed with 20 volumes of loading buffer, and
then 20 mM Tris–HCl supplemented with successive increases
of saline (250 mM–1.2 M NaCl) in 2 mL volumes, which were
collected as separate fractions. The titre of phage in each fraction
was tested as previously described and the fraction with the
highest titre of phage selected for further purification through
endotoxin-depletion.
Endotoxin was removed from the purified phage preparation
using the EndoTrap HD 5/1 kit (Hyglos) per the manufacturer’s
protocol. Here, phage preparation was diluted 1:5 in 20 mM
Tris–HCl containing 450 mM NaCl and 0.125 mM CaCl2,
passing the phage solution three times through the column.
Concentrations of endotoxin in the phage preparations before
and after purification were determined using the Endpoint
Chromogenic Limulus Amebocyte Lysate (LAL) assay (Lonza),
using endotoxin-free reagents and equipment. A high titre
phage preparation (1011 PFU/mL), generated as previously
described, was tested diluted in endotoxin-free water diluted
10−8 (103 PFU/mL) to reach the detectable range of the
kit. Purified phage preparations were tested in duplicate at
1:5 dilution in endotoxin-free water and the concentration
interpolated from a standard curve using a 3PL curve fit in
GraphPad Prism software.
Study Participants and Epithelial Cell
Collection
This study was carried out in accordance with the
recommendations of the National Health and Medical Research
Council of Australia’s National Statement on Ethical Conduct
in Human Research with written informed consent was
obtained from the parent or guardian of all participants. All
participants gave written informed consent in accordance with
the Declaration of Helsinki. The study was approved by St. John
of God Health Care Human Research Ethics Committee Ref#901
sub-study 901.1050 and by the Princess Margaret Hospital for
Children Ethics Committee Ref#1762EPP. Sixteen individual cell
cultures derived from children with CF (n = 8) and from healthy
non-CF children (n = 8), aged from 0–6 years were collected.
Median ages of participants with or without CF were not
significantly different (3.0 vs. 3.2 years old, respectively; p = 0.88),
nor proportions of females in each of these groups (37.5% vs.
50%, respectively; p = 0.60). Parental consent was obtained prior
to bronchial brushing and cells collected as described previously
(Kicic et al., 2006; Sutanto et al., 2011). Epithelial cells were
purified by removal of CD68+ cells and the epithelial phenotype
confirmed (Lane et al., 2005; Kicic et al., 2006; McNamara et al.,
2008). Demographics of the study cohort are shown in Table 1.
Cell Cultures
Children with CF had cell samples collected during bronchoscopy
as part of their annual clinical surveillance program (Sutanto
et al., 2011). In addition, cells from non-CF controls were
collected from children during elective non-respiratory related
surgery where intubation was required.
Primary airway epithelial cells derived from bronchial
brushings were conditionally reprogrammed, a method which we
previously reported resulted in cells that retain their phenotype
and functionality in culture (Martinovich et al., 2017). Briefly,
airway epithelial cells were co-cultured with irradiated fibroblasts
and grown on tissue culture-grade flasks that were pre-coated
with fibronectin and type I collagen (Kicic et al., 2006). Cells were
grown to 90% confluence in pre-coated flasks in culture media
for approximately 5 days, and then seeded into 96-well plates at
∼20,000–40,000 cells/well in growth media containing bronchial
epithelial basal medium (BEBM R©; Lonza, Basel, Switzerland)
supplemented with SingleQuot additives. All cell cultures were
at passage 3 at time of experiments and were maintained at
37◦C in an atmosphere of 5% CO2 under aseptic conditions.
Experiments were conducted on multi-layered primary airway
epithelial submerged cultures which exhibit typical cobblestone
morphology (Figure 1).
Stimulation of Cell Cultures
Prior to exposure to phage, media in 96-well plates was changed
to starvation media (growth medium minus bovine pituitary
extract, epidermal growth factor, and antibiotics) for 24 h.
Cells were then exposed to saline control or phage treatments
in infection media (media minus bovine pituitary extract and
antibiotics). The following treatments were applied to cells as 10%
of the medium in 90% v/v infection media: (1) isotonic saline, (2)
E79 phage (ratio 1:1 per epithelial cell), and (3) E79 (ratio of 10:1
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FIGURE 1 | Phase contrast images of confluent primary airways cell cultures
obtained using conditionally reprogrammed method. Epithelial cobblestone
morphology is typically maintained and observed in both healthy non-CF (A)
and CF (B) primary cell cultures. Representative image of eight subjects per
phenotype. Magnification 100×.
per epithelial cell). Cells were then incubated for 48 h at 37◦C
in 5% CO2. After exposure, cell supernatant was collected from
replicate wells, pooled and frozen at −80◦C until batch cytokine
analyses were performed. Following removal of supernatant from
96-well plates, cell viability was assessed.
Cytokine Detection in Cell Culture
Supernatants
The concentration of IL-8 in culture supernatants was
determined using enzyme-linked immunosorbent assays
(ELISA; R&D Systems) previously used in our laboratory (Kicic
et al., 2016). Values were interpolated from a standard curve with
a range of 3.125–200 pg/mL of IL-8. IL-6 was measured in culture
supernatants using a time-resolved fluorescence immunoassay as
previously described (Taylor et al., 2007; Sutanto et al., 2011) with
a minimum detectable value of 3 pg/mL. The concentration of
IL-1β in cell culture supernatants was tested using commercially
available ELISA kits, according to the manufacturer instructions
(eBioscience), with a limit of detection of 2 pg/mL. Fluorescence
and absorbance measurements for immunoassays were detected
using the ClarioStar plate reader (software version 5.20 R5 from
BMG Labtech). Concentrations of cytokines were interpolated
from measurements using a standard curve used in the same
assay. Data were transformed using the calculation x = log(x)
and a 4-parameter logistic curve fit in GraphPad Prism software.
Any values falling below the limit of detection were assigned a
value of half the lowest detectable concentration multiplied by
the dilution factor. Following interpolation of concentrations,
they were back-transformed using x = 10x.
Cell Viability and Apoptosis
Measurements
Airway epithelial cell viability was determined using the CellTiter
96 Aqueous Non-Radioactive Cell Proliferation Assay Kit
(Promega). Following incubation as instructed, absorbance of
each well was measured at 492 nm using a plate reader.
A control well without cells was used to determine background
absorbance. The percentage viability in each treatment well was
then compared to the calculated mean control value. Mean values
from at least three technical replicate wells were used in final
calculations.
Apoptosis was measured in cells exposed to phage for 48 h
using a ssDNA apoptosis ELISA Kit (Merck Millipore) as
previously described (Sutanto et al., 2011; Kicic et al., 2016).
Briefly, following exposure, culture supernatant was removed,
and cells were fixed using 200 µL per well of a solution containing
80% methanol and 20% PBS. Plates were then air dried for
30 min at RT and stored at 4◦C until batch analyses of apoptosis
were performed. The percentage of apoptotic cells compared
to untreated controls was then determined where data were
normalized to the control apoptosis value for that plate.
Statistical Analyses
Continuous variables were tested for normality using a
Shapiro–Wilk test. Since most variables did not follow a
normal distribution, non-parametric tests were used. Categorical
variables in the CF and healthy non-CF cohorts were compared
using a Chi-squared test, and continuous clinical variables were
compared using a Mann–Whitney test. Cytokine measurements
were presented as both absolute concentrations measured in
supernatants adjusted for viable cell numbers, and for the
purposes of comparing between the CF and healthy non-CF
groups, cytokine levels in phage treated wells were normalized
to the saline well as a ratio of 1. Paired data including results
from cell culture experiments and bacterial minimum inhibitory
concentration assays were compared using a Friedman test
or Wilcoxon signed-rank test, comparing phage treatments to
the control (saline), with Dunn’s post-test applied for multiple
comparisons where appropriate. Unpaired data comparing
cytokine fold-change in phage-treated wells between CF and
HNA were compared using Mann–Whitney tests. All statistical
analyses were performed in SPSS v24 (IBM). In all tests, a p-value
<0.05 was considered statistically significant.
RESULTS
Isolation of Clinically Derived Phage
One P. aeruginosa phage (P5) was successfully isolated from
patient sputum by direct plating and propagated on patient
strain PMH5. Six other phages were observed as plaques on
lawns of bacterial isolates derived from CF patients, but could
not be successfully propagated to high titre or were unstable at
4◦C in storage, and thus were not investigated further. In total,
6/20 (30%) CF-derived P. aeruginosa were demonstrated to carry
spontaneously inducible lysogenic phages.
Phage Host Ranges
Plaque formation by E79 was observed on lawns of 20/22 (91%)
of P. aeruginosa strains tested (Table 2), making it a strong
candidate for further testing as a potential therapeutic phage.
F116 and P5 had more limited host ranges (36 and 64% strains
susceptible, respectively), and were known (F116) or suspected
(P5) temperate phages, and were therefore eliminated from
further screening, since these were not considered to be ideal for
phage therapy.
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TABLE 2 | Host range of phages within the panel of clinical P. aeruginosa isolates
and PAO1 strain.
P. aeruginosa strain Colony phenotype Phage susceptibility
E79 F116 P5
PAO1 Smooth ++ ++ ++
PMH1 Mucoid ++ – ++
PMH2 Smooth ++ – –
PMH3 Mucoid ++ – –
PMH4 Mucoid ++ – +
PMH5 Smooth ++ + ++
PMH6 Rough ++ – –
PMH7 Mucoid ++ – +
PMH9 Smooth – – ++
PMH10 Mucoid – – ++
PMH11 Rough ++ + ++
PMH12 Mucoid ++ – –
PMH13 Smooth ++ + ++
PMH14 Smooth ++ – –
PMH15 Mucoid ++ – –
PMH16 Rough ++ – –
PMH17 Smooth ++ – +
PMH18 Rough ++ – –
PMH19 Mucoid ++ + +
PMH20 Mucoid ++ ++ ++
PMH22 Mucoid ++ + +
PMH23 Rough ++ + +
++Indicates complete clearing, +indicates partial clearing, –indicates no visible
clearing of the bacterial lawn.
E79 Genetic and Morphological
Characterization
Both E79 and P5 were confirmed to be double-stranded DNA
phages, demonstrated by digestion by HindIII and BamHI,
respectively (not shown). TEM of E79 identified the phage
to have a head diameter of 63.6 ± 3.8 nm, head length of
60.5 ± 5.7 nm, tail width of 8.4 ± 0.8 nm, tail length of
128.1 ± 3.7 nm, and a sheath width of 16.6 ± 2.4 nm. Genome
sequencing of E79 generated 2.2 M reads with an average length
of 252 bp. The sequencing analysis returned a complete genome
of 66,061 bp, with BLASTN analysis revealing 98% query cover
and 97% identity to a range of widespread PB1-like Pseudomonas
phages in the Myoviridae family (Ceyssens et al., 2009). The E79
genome contained 96 open reading frames, 75 of which were for
hypothetical phage proteins. No virulence factors or antibiotic
resistance genes were detected, nor any genes from the host
PAO1 bacterial genome. The full sequence of E79 is deposited in
GenBank under accession #MH536736.
Phage Purification
Phage fractions were collected from the ion-exchange
chromatography column and examined for remaining viable
phage. Approximately 80% of the added phage was recovered in
the saline fractions collected. Maximal phage recovery occurred
from the elution at approximately 450 mM NaCl (Figure 2B).
The concentration of endotoxin in the filter-sterilized phage
(unpurified) and the purified, endotoxin-depleted phage
preparations was approximately 108 and 1.9 EU/mL, respectively.
E79 phage preparations were stored at 4◦C and retained the high
infective titre for >20 weeks of testing (Figure 2A).
Bacterial Growth Inhibition
Growth of clinical P. aeruginosa isolates was significantly
decreased (median 33% decrease) in the MOI 1:1 (low phage
ratio) and MOI of 10:1 (high phage ratio) (median 23% decrease).
Of 14 clinical isolates tested, a variety of growth inhibition and
clinical antibiotic resistance phenotypes were observed (Table 3)
with 11 (79%) showing some growth inhibition by E79. Of these,
eight (57%) exhibited single or multiple antibiotic-resistance.
Response of Airway Epithelial Cells to
Stimulation
Viability of airway epithelial cells from children with CF or
healthy non-CF controls was not affected when treated with
FIGURE 2 | Stability and recovery of E79 phage after purification steps. (A) Titre of E79 phage was retained over long term storage at 4◦C, determined by the
drop-on-plate method using PAO1 as the propagating host strain. (B) Recovery of E79 in fractions from ion-exchange chromatography column. Data show average
values obtained from three replicate measurements of a single solution.
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FIGURE 3 | Survival of primary airways cells exposed to phage. Apoptosis in
cell cultures exposed to phage at high or low concentration relative to saline
controls. Average individual values are shown from three replicate wells, and
bars indicate the group median value. Statistically significant differences in
Friedman post-tests (p < 0.05) are indicated by p-values.
phage at either ratio (data not shown). Similarly, E79 phage
did not induce apoptosis in either phenotype at either the low
or high phage ratio (Figure 3); rather exposure to phage was
associated with lower apoptosis levels than observed in control
wells.
Comparing 8 non-CF and 8 CF cultures treated with
phage suspensions at low or high ratio, there was no induced
inflammatory cytokine production (Figure 4). Specifically, no
significant increase in IL-1β, IL-6, and Il-8 was observed when
CF or healthy non-CF cells were treated with low or high phage
titres (p > 0.05; Figure 4).
DISCUSSION
New antibacterial therapies are urgently required to counteract
the rise of multidrug-resistant microbes. In this work, we
successfully propagated and screened three bacteriophages and
identified that the P. aeruginosa-infecting phage E79 had
the broadest host range of these. Moreover, the protocol
utilized to purify phage was successful in removing bacterial
contaminants to the extent that no significant apoptosis,
or inflammatory cytokine production was detected in either
airway epithelial cells from children with CF or healthy
non-CF controls after 48 h of co-culture with purified
E79 phage. Collectively, this work demonstrates a proof of
concept that a screening approach utilizing bacteriophage
and primary epithelial cells derived from the CF population
could be applied for the development of new therapies for
people with CF-associated antibiotic-resistant bacterial lung
infections.
Given the association of P. aeruginosa airway infections
and pulmonary decline in people with CF, early intervention
when children are first infected could be critical in preventing
lung damage and increase life expectancy (Ranganathan et al.,
2017). Inhaled phage therapy is one option that could be
utilized in combination with current therapies to improve
outcomes. The optimal dosing formulations and regimes would
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FIGURE 4 | Cytokine production in primary airways cells exposed to phage. Levels of (A) IL-1β, (B) IL-6, and (C) IL-8 cytokines in culture supernatants of cells
exposed to treatments for 48 h compared with untreated controls cell. Cytokine concentrations were adjusted for the ratio of viable cells in the phage treatment wells
compared with the control well. Data show values for healthy non-CF children (open circles; n = 8) or children with CF (closed circles; n = 8) representing the mean
calculated from three replicate treatment wells per individual. Horizontal lines represent the group (healthy non-CF or CF) median.
need to be determined in clinical trials following identification
of ideal phage candidates, using pre-clinical models such as
the one described here. A limited number of case studies
are described in the literature on treatment of airways
infections in children with CF with phage therapy, as well
as a number of reports on use in uncontrolled studies in
CF and non-CF adults (Sulakvelidze et al., 2001; Kutateladze
and Adamia, 2008; Kvachadze et al., 2011; Abedon, 2015;
Hoyle et al., 2018). Encouragingly, these early reports suggest
that phage therapy may be feasible in the pediatric CF
population.
Our pre-clinical screening method demonstrated that almost
half of P. aeruginosa isolates carried one or more spontaneously
released phages. It is likely that these phages were temperate,
and therefore may not be ideal for therapeutic use (Hraiech
et al., 2015), although we did not confirm this with genome
sequencing. Isolation and propagation to high titre proved
difficult for most of these phages. The prevalence of non-
propagatable isolates in this study is not unique (Serwer et al.,
2004), and isolation techniques could be optimized in future,
such as inclusion of antibiotics in culture media (Santos et al.,
2009). Despite the potential for lysogenic phages to confer
resistance to related phages (Labrie et al., 2010; James et al.,
2012; van Houte et al., 2016), each bacterial isolate utilized for
screening of host ranges here was susceptible to at least one phage
tested for activity, indicating that the children from whom the
bacteria were isolated could potentially be treated with phage
therapy.
We found that the virulent phage, E79, had many ideal
characteristics for further development as a therapeutic phage,
including stability in high titre preparation, broad infective
capacity of clinical P. aeruginosa isolates, and lack of known
bacterial pathogenicity genes. Indeed, PB1-like phages such as
E79 are considered by some to be among the most promising
for application in phage therapy (Krylov et al., 2015) due
in part to the low frequency of mutation to phage-resistance
(Ceyssens et al., 2009). On the other hand, an earlier study
suggested that E79 had restricted access to the deeper layers
of a biofilm of PAO1 generated on glass (Doolittle et al.,
1996), although the authors stated that fluorescently labeling
the phage significantly affected infective capacity and that they
could not determine whether the decrease in signal deeper in the
biofilm was an experimental artifact. In another study, biofilm
challenge with E79 resulted in a transient increase at 24 h in
biofilm formation, although following further incubation, biofilm
decreased (Hosseinidoust et al., 2013). Despite the limitations
of extrapolating artificial biofilm methods to human CF lungs,
which have very different environmental conditions that might
affect bacterial growth, these are important issues to address
for phage therapy. Certainly, further characterization would be
required for clinical development in a more disease-appropriate
model system. Here, to determine bacterial infective capacity, we
used a qualitative drop-on-plate assay and an indirect optical
density assay of bacterial viability. Whilst these assays may give
some indication of a phage’s broad infective capacity of various
bacterial strains, more accurate prediction of clinical outcomes
in patients would ideally involve quantitative measurement of
phage activity in a biofilm model, ideally including live/dead cell
imaging.
Phage-host dynamics are complex with pharmacokinetic
interactions that may not be correctly predicted without
including as many components as possible of the phage-bacterial-
host cell interaction in a model. In vivo, it is predicted that
the human immune system would work in a complementary
manner to phage to control bacterial growth. Roach et al.
(2017) reported that neutrophils are important for immunophage
synergy and immunodeficient mice did not respond to phage
treatment of P. aeruginosa pneumonia in the same manner
as immunocompetent mice. Therefore, simple antimicrobial
assays may not accurately predict clinical consequences of
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novel treatments. Given the differences between healthy and
CF neutrophil phenotypes (Gray et al., 2018), it is critical to
examine immunophage synergy for people with CF in a relevant
model for these individuals, and as such it may be possible to
include neutrophils or other immune cells in an airways co-
culture model. Although we did not include any non-epithelial
cells in this model, one major focus was adequate purification
of phage preparation. Given that human airways epithelial cells
express a range of Toll-like receptors (Ritter et al., 2005), and our
work assessed upregulation of downstream cytokines from NF-
κB activation, our model was sufficient for this aim. The response
of primary cells derived from different children was personalized;
though overall, phage preparations did not induce cytokine
production, in some individuals, production of inflammatory
cytokines in response to phage exposure was elevated when
compared to untreated cells. Despite this, as a group (CF or
non-CF children) the differences between phage-exposed and
control cell cultures were not statistically significant. Therefore,
our data suggest that personalized screening approaches may be
best to determine the appropriate treatment for people with CF,
where grouped results may not be representative of outcomes
for all individuals within that group. However, the method used
here in this pilot study could be significantly improved in future
by one or all of the following: (a) use of air-liquid interface
(ALI) in primary respiratory cell cultures, (b) examination of
biofilm, (c) addition of professional immune cells in co-culture
with respiratory cells, and (d) delivery of aerosolised phage
preparations.
The phage purification methods used here were comparable
to those used successfully by others, and resulted in depletion
of endotoxin and other bacterial signatures that might have
activated epithelial cell inflammatory responses. However, it
is likely that without extra preparatory steps, host DNA
contamination may be an issue for phage preparations (Kleiner
et al., 2015). In addition, it is possible that the decreased levels
of apoptosis in phage suspension-treated cells compared with
saline-exposed cells is a host cell pro-survival response to damage
caused by other PAO1 contaminants remaining in the phage
preparation (Wu et al., 2011). Given that we did not find any
PAO1-associated genes in the E79 genome, our methods to
remove free host DNA were successful, and therefore, it may
be appropriate to utilize a similar DNase treatment step to
avoid potential transfer of host bacterial genes to bacteria in
the human airways, as previously suggested (Pirnay et al., 2015).
Previous work with other phages has shown different methods of
pharmacological preparation affect viability and particle sizing,
which are relevant for inhalation of phages (Leung et al., 2016).
In the CF lung environment, it will be important to determine
the pharmacological formulations that best allow phages to
survive the preparation steps and to enter the lungs with optimal
aerodynamic properties in an inhaled formulation (Chang et al.,
2017). The activity of optimized phage formulations in the lung
environment can be investigated using models of the CF airway,
although more purification steps should be taken with phage
preparations in future.
In this study, of eight clinical isolates of P. aeruginosa
that displayed some level of resistance to single or multiple
antibiotics, seven exhibited E79 phage-susceptibility at the
highest MOI tested, while two out of six antibiotic-susceptible
isolates were E79 phage-resistant. This preliminary result
suggests that the combined use of traditional antibiotics and
phages might be a good approach in at least some cases of
antibiotic-resistant infections. Rossitto et al. (2018) have noted
the limited number of investigations of combined antibiotic-
phage treatment, but consider this a promising approach for
the future of anti-P. aeruginosa therapy in CF. The rate of
progress from bench to bedside that might be predicted by the
ease with which novel phages are isolated is in fact limited
by the uncertainty surrounding their safety. This situation
arises, in part, from inadequate characterization of these phages
in clinically relevant CF models. Therefore, in future, the
process of selecting phages for therapeutic development could
be performed as a high-throughput methodology for people
with CF, identifying phages that are suitable for their particular
infecting bacterial strain and immunological idiosyncrasies, and
determining appropriate dosage using appropriate personalized
in vitro models.
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